Home Biosimilar Antibodies Proteases PSMA Rosopatamab (Anti-FOLH1 / PSMA)
For research use only. Not for use in humans.

Rosopatamab (Anti-FOLH1 / PSMA)

Synonyms: HJ 591

Rosopatamab (Anti-FOLH1 / PSMA) is a humanised monoclonal antibody targeting PSMA. It can be used in cancer research, particularly in prostate cancer. MW: 144.36.

Rosopatamab (Anti-FOLH1 / PSMA)

Quality Control

Batch: A261701 Purity: 99% Protein concentration: 7mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Rosopatamab (Anti-FOLH1 / PSMA) is a humanised monoclonal antibody targeting PSMA. It can be used in cancer research, particularly in prostate cancer. MW: 144.36.
References

Product Details

CAS No. 2260767-49-3
Molecular Weight 144.36
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07200830 RECRUITING Drug: Lutetium Lu 177 Vipivotide Tetraxetan Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 Alliance for Clinical Trials in Oncology 2026-03-31 PHASE3
NCT06600802 RECRUITING Castration-resistant Metastatic Prostate Cancer; Treated by 177Lutetium-PSMA-617 (Lu-PSMA) Centre Jean Perrin 2024-10-08
NCT07426094 RECRUITING Drug: Androgen Deprivation Therapy (ADT)|Drug: Androgen Rece Prostate Cancer; Brachytherapy; Stereotactic Body Radiation Therapy (SBRT); Dose Escalation: Solid Tumors; Regionally Advanced Prostate Cancer Affidea Nu-med Center of Oncological DIagnostics and Therapy 2026-03-19 PHASE2; PHASE3
NCT07426055 RECRUITING Drug: Androgen Deprivation Therapy (ADT) Prostate Cancer (Adenocarcinoma); Prostate Brachytherapy; Stereotactic Body Radiation Therapy (SBRT); Dose Escalation: Solid Tumors; Localized Prostate Cancer Affidea Nu-med Center of Oncological DIagnostics and Therapy 2026-03-19 PHASE2; PHASE3
NCT07237269 RECRUITING Drug: Androgen Deprivation Therapy (ADT)|Drug: Abiraterone|D Prostate Cancer University of Nebraska 2026-10-15 PHASE2
NCT05896371 NOT_YET_RECRUITING Drug: 177Lu-PSMA-I&T - escalating renal absorbed dose|Drug: Cancer; Prostate Cancer; Metastatic Cancer; Metastatic Prostate Cancer CHU de Quebec-Universite Laval 2028-03 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.